flatexDEGIRO appoints Oliver Behrens, long-standing CEO of Morgan Stanley Europe SE, as Chief Executive Officer
28.8.2024 10:51:00 EEST | Business Wire | Press release
Oliver Behrens appointed as new Chief Executive Officer (CEO)
flatexDEGIRO AG (the “Company”), one of the leading and fastest growing online brokers in Europe, announces that the Company’s Supervisory Board has appointed Oliver Behrens (60) as Chief Executive Officer (CEO) of flatexDEGIRO AG, effective from October 1, 2024, for a duration of three years. Furthermore, Oliver Behrens will also take over as CEO of flatexDEGIRO Bank AG.
Oliver Behrens brings 40 years of experience in the European financial industry with a strong link to brokerage and an outstanding network in international finance and politics.
From 2015 to June 2024, Oliver Behrens lately was CEO of Morgan Stanley Europe Holding SE, Morgan Stanley Europe SE and Morgan Stanley Bank AG, Frankfurt am Main, as well as Member of the Board of Morgan Stanley International Limited, London. Moreover, until 2014, he also served as Member of the Board of Deka-Bank for nine years, lately as Deputy CEO. From 1992 to 2005, he worked in Frankfurt and Luxembourg, among others, across various functions in the former DWS Group, DWS and Deutsche Asset Management, where he was lately Spokesman of the Management Board of Deutsche Asset Management Investment GmbH. Since June 2024, Oliver Behrens is Chairman of DWS Group GmbH & Co. KGaA’s Supervisory Board.
Oliver Behrens takes over from Dr Benon Janos (52) and Stephan Simmang (58), who, since May 1, 2024, serve as interim Co-CEOs of the Company, in addition to their existing responsibilities as CFO and CTO, respectively.
On his appointment as new CEO of flatexDEGIRO AG, Oliver Behrens commented: "The European online brokerage business is still in its early innings, holding enormous potential for growth and value enhancement. Together with flatexDEGIRO’s strong leadership team, I am very much looking forward to leading the company into the next phase of its evolution, further enhancing the investment experience for millions of clients across 16 countries while firmly establishing flatexDEGIRO as the driving force in the European online brokerage market.”
Martin Korbmacher, Chairman of flatexDEGIRO’s Supervisory Board, said: “With Oliver Behrens, we have succeeded in engaging a real heavyweight of the European financial industry for this leading role at flatexDEGIRO. It fills us with pride and speaks for the great potential of flatexDEGIRO that we have been able to recruit an executive of his caliber for the vacant CEO position. With his outstanding industry experience and his strong, team-orientated leadership personality, Oliver Behrens is a real gain, both operationally and organizationally, for our company which he already knows very well from the long-standing and cooperative business relationships with his previous employer.”
The appointment of Oliver Behrens as CEO of flatexDEGIRO AG and flatexDEGIRO Bank AG is subject to customary approvals by the German Federal Financial Supervisory Authority (BaFin).
Appointment of Dr Benon Janos (CFO) as Deputy CEO
Moreover, the Company’s Supervisory Board has appointed Dr Benon Janos (CFO) as Deputy CEO of flatexDEGIRO AG, effective from October 1, 2024. Dr Benon Janos will also fulfil this function at flatexDEGIRO Bank AG.
Contract extension of Dr Benon Janos (Deputy CEO & CFO) and Stephan Simmang (CTO) until mid-2029
Furthermore, the Supervisory Board of flatexDEGIRO has also decided to extend the Management Board contracts of Dr Benon Janos (Deputy CEO & CFO) and Stephan Simmang (CTO) until May 31, 2029. Dr Benon Janos and Stephan Simmang have held management positions at flatexDEGIRO since 2016, serving as members of the Company’s Management Board since 2023.
Therefore, effective from October 1, 2024, flatexDEGIRO AG’s Management Board will consist of four members, namely Oliver Behrens (CEO), Dr Benon Janos (Deputy CEO & CFO), Stephan Simmang (CTO) and Christiane Strubel (CHRO).
Martin Korbmacher, Chairman of flatexDEGIRO’s Supervisory Board, said: “On behalf of the whole Supervisory Board, I would like to express our deepest gratitude to Dr Benon Janos and Stephan Simmang for stepping up and taking on additional responsibilities as Co-CEOs during the past months, ensuring a professional and orderly transition after the departure of the former CEO. The Supervisory Board is very much looking forward to extending the great collaboration over the coming years and expressly thanks Dr Benon Janos and Stephan Simmang for their leadership and integrity, especially during this critical transition phase.”
About flatexDEGIRO AG
flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR) operates one of the leading and fastest growing online brokerage platforms in Europe. Based on modern, in-house state-of-the-art technology, customers of the flatex and DEGIRO brands are offered a wide range of independent products with execution on top TIER 1 exchanges. The technological edge, high efficiency and strong economies of scale enable flatexDEGIRO to continuously improve its service offering for clients and set leading standards in terms of product, price and platform quality.
With around 3 million customer accounts and around 60 million securities transactions processed in 2023, flatexDEGIRO is one of the largest retail online brokers in Europe. In times of bank consolidation, low real interest rates and digitalization, flatexDEGIRO is ideally positioned for further growth.
Further information can be found at https://www.flatexdegiro.com/en.
| Language: | English | |
| Company: | flatexDEGIRO AG | |
| Omniturm, Große Gallusstraße 16-18 | ||
| 60312 Frankfurt / Main | ||
| Germany | ||
| Phone: | +49 (0) 69 450001 0 | |
| E-mail: | ir@flatexdegiro.com | |
| Internet: | www.flatexdegiro.com | |
| ISIN: | DE000FTG1111 | |
| WKN: | FTG111 | |
| Indices: | SDAX | |
| Listed: | Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Hamburg, Munich, Stuttgart, Tradegate Exchange |
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828514871/en/
Contacts
Achim Schreck
Head of IR & Corporate Communications
Phone +49 (0) 69 450001 1700
achim.schreck@flatexdegiro.com
Laura Hecker
Director Investor Relations
Phone +49 (0) 160 3064 404
laura.hecker@flatexdegiro.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*13.11.2026 00:07:00 EET | Press release
The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience brings Percy Jackson’s adventures off the screen and into the ‘World’s Most Famous Building,’ where guests ca
Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 19:09:00 EET | Press release
VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks to regulatory approval. To remove this barrier, Veristat uses its AI-enhanced platform to compress the timeline to submission-ready TLFs from weeks to days, with every output validated by stati
WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network12.11.2026 19:00:00 EET | Press release
WHOOP, the human performance brand, today launched WHOOP Humans, a new feature that lets members follow friends and family, share fitness, health, and performance data they choose, and support each other's progress. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112176779/en/ WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network For more than a decade, WHOOP has helped members better understand their own health and performance. Now, WHOOP Humans extends that experience beyond the individual, making it easier to celebrate achievements, encourage progress, and look out for the people who matter most. "In a world that's becoming increasingly artificial, we're building something deeply human,” said Will Ahmed, Founder and CEO of WHOOP. “This is the most verifiably human network ever launched. Every account represents a real person with a verified heartbeat. They have real goals, challenges, and achievements. T
Integrated Hubs for Green Chemistry Research Aim to Transform How Chemicals and Materials Are Designed12.11.2026 18:00:00 EET | Press release
The Gordon and Betty Moore Foundation today announced four Integrated Research Hubs to explore new frontiers in chemical design, from materials that respond to their surroundings to molecules designed for safety from the start. Bringing together global researchers across institutions and disciplines, the hubs will investigate fundamental principles that could enable new capabilities in chemicals and materials while improving performance and protecting human health and the environment. The research priorities emerged through extensive engagement with the scientific community to identify the questions that could transform what chemistry can achieve. Each hub will connect researchers across institutions around one of four green chemistry focus areas: Safer molecular design: Led by The George Washington University, this hub will combine artificial intelligence and quantum chemistry to embed safety into chemical design from the outset. Adaptive catalytic systems: Led by the Max Planck Insti
Roquette Highlights Scalable Excipient and Capsule Solutions for Regional and Global Pharmaceutical Markets at CPHI India 202612.11.2026 17:00:00 EET | Press release
Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, will showcase its comprehensive portfolio of excipient and capsule solutions at CPHI India 2026, Hall 1, Booth 1I12 from November 23 to 25, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112803410/en/ Meet Roquette at CPHI India 2026, Hall 1, Booth 1I12 At the event, Roquette will demonstrate how it helps pharmaceutical manufacturers accelerate the journey from formulation to market with confidence. By combining technical expertise, trusted quality, meaningful innovation and close collaboration, Roquette helps customers address formulation, scale-up and manufacturing challenges across a broad range of pharmaceutical applications. As India continues to play a critical role in supplying medicines to patients around the world, pharmaceutical manufacturers face increasing demands for quality, regulatory compliance,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom